Advertisement
Advertisement
Aptevo’s Promising AML Study: A Potential Game-Changer for Investors
PremiumCompany AnnouncementsAptevo’s Promising AML Study: A Potential Game-Changer for Investors
17d ago
Aptevo Therapeutics files to sell 6.9M shares of common stock for holders
Premium
The Fly
Aptevo Therapeutics files to sell 6.9M shares of common stock for holders
1M ago
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
2M ago
Aptevo says mipletamig deliver 100% remission rate in RAINIER cohort 3
PremiumThe FlyAptevo says mipletamig deliver 100% remission rate in RAINIER cohort 3
2M ago
Aptevo Therapeutics Expands Anti-Cancer Pipeline with Patents
Premium
Company Announcements
Aptevo Therapeutics Expands Anti-Cancer Pipeline with Patents
2M ago
Aptevo Therapeutics expands anti-cancer pipeline with APVO452, APVO451
Premium
The Fly
Aptevo Therapeutics expands anti-cancer pipeline with APVO452, APVO451
2M ago
Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise
PremiumCompany AnnouncementsAptevo Therapeutics Regains Nasdaq Compliance with Equity Raise
4M ago
Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance
Premium
Company Announcements
Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance
5M ago
Aptevo Therapeutics Raises $7.45M Through Stock Sale
Premium
Company Announcements
Aptevo Therapeutics Raises $7.45M Through Stock Sale
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100